H1-B Visas

I am probably one of those [postdocs] who can understand Deborah Andrew's postdoc best. I am a postdoctoral associate at the University of Miami. The university requires under the soft term "recommends" that all candidates to change status from F1 to H-1B hire a lawyer approved by the university. Fine. It cost me $1500. Anticipating that things with H-1Bs were going bad, I first contacted a "university approved" lawyer on Jan. 6, seven months before the expiration of my present employment auth

Written byAndrey Savtchenko
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

I am probably one of those [postdocs] who can understand Deborah Andrew's postdoc best. I am a postdoctoral associate at the University of Miami. The university requires under the soft term "recommends" that all candidates to change status from F1 to H-1B hire a lawyer approved by the university. Fine. It cost me $1500.

Anticipating that things with H-1Bs were going bad, I first contacted a "university approved" lawyer on Jan. 6, seven months before the expiration of my present employment authorization document, July 31, but it was not until April 30 that my application was filed with Immigration and Naturalization Service--four months for a relatively simple procedure that people usually handle by themselves.

Apparently, somewhere in the triangle lawyer-university-Immigration things were deadly slow, and the lawyer's fee and my push to make things moving were not sufficient to accelerate them. Nobody is in a position, not even my lawyer, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies